Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19
This expanded access program will provide access to investigational convalescent plasma for patients in acute care facilities infected with SARS-CoV-2 who have severe or life-threatening COVID-19, or who are judged by a healthcare provider to be at high risk of progression to severe or life-threatening disease.
This research study is led by Dr. Hans Schlecht.
Contact: Judy Pride, 413-794-6245
Primary Sponsor: Mayo Clinic
Baystate Medical Center, 759 Chestnut Street, Springfield, MA
Age at least 18 years, Laboratory confirmed diagnosis of infection with SARS-CoV-2, Admitted to an acute care facility for the treatment of COVID-19 complications and Severe or life threatening COVID-19, or judged by the treating provider to be at high risk of progression to severe or life-threatening disease.